The new Prostatefocus cancer test has been developed to identify men who are at high risk of developing prostate cancer. Credit: Oncologica UK Ltd.

Oncologica has launched the new Prostatefocus cancer genetic screening test to detect prostate cancer in men.

The new test uses a simple saliva-based self-sample collection test kit and has been designed to detect the presence of faulty DNA repair genes. 

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It has been developed to identify men who are at high risk of developing prostate cancer.

The test is offered across the UK through the company’s specialised medical healthcare partners, who also provide a pre-test consultation to explain the test process and implication of results.

Oncologica’s healthcare providers can provide the self-sampling kit or arrange for clinic sample collection.

See Also:

The collected Prostatefocus samples will be sent to Oncologica’s UKAS-accredited laboratory for genetic analysis, and the results will be made available within seven days.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

If abnormalities are found, the healthcare partner will schedule a post-test follow-up to discuss the results as well as the risk of getting prostate cancer and next steps.

Oncologica co-owner and scientific director Dr Marco Loddo said: “Better treatments have improved survival from the disease, but accurate screening for prostate cancer has proven difficult.

“Prostate cancer tends to grow slowly without symptoms, so men often present late with advanced incurable disease.

“Identifying men at high risk of developing prostate cancer means regular checks can take place so that if the disease develops at some stage during their lifetime it is picked up early.”

According to the company, 50,000 people are diagnosed with prostate cancer every year in the UK.

Last month, the company launched Allergyfocus, a new antibody allergy test that can detect 99% of common global allergies.